MADRID, Spain—Stopping oral anticoagulation (OAC) improves outcomes among patients who remain free from atrial arrhythmia recurrences for at least a year after catheter ablation for atrial ...
In the OCEANIC-AF trial, asundexian resulted in a small increase in the rates of stroke and lowered bleeding compared with apixaban in patients with atrial fibrillation (AF) who were naive to oral ...
Despite secondary prevention with oral anticoagulation (OAC), the risk for recurrent ischemic stroke (IS) and mortality is high in patients with atrial fibrillation (AF). However, OAC discontinuation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback